HIV-1 Tat has been the vanguard of Pol II transcription elongation control for more than two decades 3.Nevertheless, its mechanism of action has ceased to be recognized as a viral peculiarity only ...

Early steps of infection by HIV-1 involve entry of the viral core into cells, reverse transcription to form the linear viral DNA, and integration of that DNA into a chromosome of the host.

After removing the nucleos(t)ide analog reverse-transcriptase inhibitor monophosphate, the mode of DNA polymerization becomes active again (bottom). The P site and N site of HIV-1 reverse ...

The four main classes, which most people are treated with, target one of three viral proteins which control HIV’s lifecycle: reverse transcriptase, integrase and protease. Historically, most people ...

The major focus of our research is on the HIV Tat protein, which is essential for HIV transcription, and on two cellular factors, cyclin T1 and Cdk9, which are necessary for Tat function. We are ...

Specific subtypes and transmission clusters for HIV could require targeted interventions to control spread of HIV that is ...

Because of these differences in the silencing machinery we have been able to identify selective activators of HIV transcription in the two different cell types. Extending this work we plan to develop ...

On left, the HIV virus binds to CD4 T cell CD4 receptor, which will allow the ... [+] co-receptor CCR5 to melt and release the viral RNA into the cytoplasm. After reverse transcription ...

It is an ester-derived prodrug that is converted in vivo by serum and tissue esterases to tenofovir, an acyclic nucleoside phosphonate (nucleotide) that inhibits HIV reverse transcriptase.

More than 46,000 of them had been prescribed a form of HIV-suppressing medications known as reverse transcriptase (RT) inhibitors. Among this subgroup, Alzheimer's diagnoses occurred in about 2.5 ...

Gilead Sciences and MSD are advancing their once-weekly HIV treatment regimen to Phase ... an experimental nucleoside reverse transcriptase inhibitor, with Gilead’s lenacapavir, marketed as ...